NCT05197504Completed
Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy
Biomarker Discovery Through Multiomics Study in Advanced Hepatocellular Carcinoma Patients Who Received Atezolizumab and Bevacizumab Combination Therapy
Source: ClinicalTrials.gov · Last updated 5 Sept 2025
Brief summary (registry, in English)
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, and HCC is more frequently observed in Asia, including South Korea. As HCC is often accompanied by chronic hepatitis B or C virus and liver cirrhosis, treatment of HCC consider not only the tumor but also various factors such as liver function and the patient's performance status. Local treatment and surgery are possible in the early stages of HCC. However, it has a high recurrence rate even after curative surgeries due to underlying cirrhosis and the tumor microenvironment. Although several studies have investigated gene mutations and differences in treatment response in advanced HCC through next-generation sequencing (NGS), studies on transcriptome analysis of advanced HCC through RNA-sequencing are hard to find, with a need for future research into precise classification and clinical significance of HCC based on multi-omics data.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 166 (actual)
- First submitted
- 24 Dec 2021
- Start date
- 20 Dec 2021
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- CHA University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05197504
What you commit to
- Study type: Observational
- Participants enrolled: 166
- From 20 Dec 2021 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure
- Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form
Other
- Those who are assessed as not suitable for this study, at the discretion of the researcher
Who the study is looking for
- Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
- Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
- Patients who underwent an NGS test with advanced HCC tissues
- Patients who are scheduled to receive systemic treatment
- Patients with measurable lesions based on RECIST v1.1
- ECOG performance status 0 or 1
- Patients with a life expectancy of at least three months
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHA Bundang Medical Center Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.